BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28709825)

  • 21. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.
    Urban EM; Chapoval AI; Pauza CD
    Clin Dev Immunol; 2010; 2010():732893. PubMed ID: 20396597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of γδ T cells in α-galactosylceramide-mediated immunity.
    Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
    J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Function of γδ T cells in tumor immunology and their application to cancer therapy.
    Park JH; Lee HK
    Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosurveillance and immunoregulation by gammadelta T cells.
    Girardi M
    J Invest Dermatol; 2006 Jan; 126(1):25-31. PubMed ID: 16417214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-lymphoma effect of gammadelta T cells.
    Kunzmann V; Wilhelm M
    Leuk Lymphoma; 2005 May; 46(5):671-80. PubMed ID: 16019504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human γδ thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling.
    Ribot JC; Ribeiro ST; Correia DV; Sousa AE; Silva-Santos B
    J Immunol; 2014 Mar; 192(5):2237-43. PubMed ID: 24489097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.
    Haas JD; González FH; Schmitz S; Chennupati V; Föhse L; Kremmer E; Förster R; Prinz I
    Eur J Immunol; 2009 Dec; 39(12):3488-97. PubMed ID: 19830744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
    Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
    Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. γδ T cells are indispensable for interleukin-23-mediated protection against Concanavalin A-induced hepatitis in hepatitis B virus transgenic mice.
    Meng Z; Wang J; Yuan Y; Cao G; Fan S; Gao C; Wang L; Li Z; Wu X; Wu Z; Zhao L; Yin Z
    Immunology; 2017 May; 151(1):43-55. PubMed ID: 28092402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells.
    Tawfik D; Groth C; Gundlach JP; Peipp M; Kabelitz D; Becker T; Oberg HH; Trauzold A; Wesch D
    Front Immunol; 2019; 10():2044. PubMed ID: 31555275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
    Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
    Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
    Front Immunol; 2020; 11():564499. PubMed ID: 33133075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?
    Riganti C; Massaia M; Davey MS; Eberl M
    Eur J Immunol; 2012 Jul; 42(7):1668-76. PubMed ID: 22806069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. γδ T-cell conference 2012: close encounters for the fifth time.
    Silva-Santos B; Schamel WW; Fisch P; Eberl M
    Eur J Immunol; 2012 Dec; 42(12):3101-5. PubMed ID: 23255005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
    Martinet L; Poupot R; Fournié JJ
    Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].
    Catros V; Toutirais O; Bouet F; Cabillic F; Desille M; Fournié JJ
    Med Sci (Paris); 2010 Feb; 26(2):185-91. PubMed ID: 20188051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.
    Marquez-Medina D; Salla-Fortuny J; Salud-Salvia A
    Clin Transl Oncol; 2012 Dec; 14(12):891-5. PubMed ID: 23054752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
    Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
    Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.